

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and Waiver under 18 U.S.C. §208(b)(3)

Louis Morris, Ph.D.

Committee: Arthritis Drugs Advisory Committee

Meeting Date: November 29, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the committee's discussions of the safety and efficacy of New Drug Application NDA 20-998, supplement 021, trade name, Celebrex (celecoxib), a non-steroidal anti-inflammatory drug (COX-2 inhibitor), manufactured by Searle Ltd. for G.D. Searle LLC, subsidiaries of Pfizer, for the proposed indication of the relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) in patients two years and older. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Consulting	Competing Firm	Less than \$10,001 per year.
Unrelated Consulting	Competing Firm	Less than \$10,001 per year.
Expert Witness (unrelated) for a law firm representing a competing firm.	Competing Firm	Greater than \$50,000 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

_____/S/_____
Signature of SGE

November 9, 2006
Date

